COPD: A Phase 2a clinical trial is ongoing for the treatment of COPD and completed in May 2018.
Mercury poisoning: The Company has Orphan Drug Designation for the Prevention and Treatment of Mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed.
Other conditions: Preclinical studies ongoing for other indications.
Early access/Individual Patient treatments: There are a growing number of approvals and shippings to Switzerland, Germany, Austria, New Zealand, UK and the USA for Individual Patient use. For more information – please click above.
Subscribe To Our Mailing List: (* indicates required)